Tixagevimab,Cilgavimab
AstraZeneca
[]
l08 #acr22 tix/cil (evusheld) in rheum pts
157 pts, f/u 154 days
24 breakthrough covid ifns (15%)
2 pts required hospitalization, rest had mild-mod symptoms
no saes (cvd) 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land